INmune Bio has entered the U.S. national phase for its CORDStrom™ platform patent application after receiving a favorable international patent opinion. This patent covers their mesenchymal stromal cell (MSC) platform, including the lead product Ebstrocel for epidermolysis bullosa, and aims to protect next-generation engineered therapies. If granted, the patent will provide exclusive commercial rights until at least 2045, supporting the company's long-term market strategy. INmune Bio plans to pursue additional patents globally to strengthen its intellectual property portfolio as it advances clinical and regulatory milestones.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Bitcoin holders who bought between $107,000 and $118,000 are facing significant losses in 2026, signaling a possible bear-market bottom similar to previous cycles in 2018, 2020, and 2022. On-chain data from Glassnode shows realized losses peaking and...
Ethereum has strengthened its position as the top staking network with a 12.13% weekly increase in staked market cap, reaching $78.08 billion. This growth highlights a shift of investor interest back to large-cap, liquid networks despite mixed result...
A Bitcoin wallet that had been inactive since December 2017 transferred 5,908 BTC worth about $383 million on July 16, 2026. Originally acquired at around $16,000 per Bitcoin, the initial investment was roughly $100 million, now showing a 284% gain. ...
